In recent years, next-generation sequencing (NGS)–based genetic testing has become crucial in cancer care. While its primary objective is to identify actionable genetic alterations to guide treatment decisions, its scope has broadened to encompass aiding in pathological diagnosis and exploring resistance mechanisms. With the ongoing expansion in NGS application and reliance, a compelling necessity arises for expert consensus on its application in solid cancers. To address this demand, the forthcoming recommendations not only provide pragmatic guidance for the clinical use of NGS but also systematically classify actionable genes based on specific cancer types. Additionally, these recommendations will incorporate expert perspectives on crucial biomarkers, ensuring informed decisions regarding circulating tumor DNA panel testing.

Although the proportion of edentulous patients is declining, the aging population has resulted in an increase in their absolute numbers. Conventional complete dentures can partially restore oral function but have significant limitations such as low retention and relatively poor masticatory ability. Therefore, implant overdentures have been proposed as an alternative, offering enhanced functionality, higher patient satisfaction, and cost-effectiveness compared to fixed implants. In this case, a 74-year-old female patient presented with complaints about her existing implant overdenture, fabricated in 2010, which frequently dislodged and was aesthetically unpleasing. Clinical examination revealed worn attachments and artificial teeth, as well as insufficient upper lip support. It was decided to remake the implant overdentures utilizing the existing implants. During the fabrication, the patient continued to use her previous denture. After evaluating the occlusal relationships, facial form, and vertical dimension, the new overdentures were fabricated. The newly created implant overdentures showed satisfactory aesthetic and functional results, and the patient was satisfied.

The diagnosis of acute ischemic stroke (AIS) can be challenging when neuroimaging findings are normal or equivo‑ cal. Neutrophil extracellular traps (NETs), particularly histone H3.1, have potential as biomarkers for AIS. This study evaluated NETs, specifically histone H3.1, as diagnostic biomarkers for AIS. This prospective study included 89 patients with AIS and 20 healthy controls. Plasma histone H3.1 levels were measured using the Nu.Q® H3.1 enzyme-linked immunosorbent assay (ELISA). Seven cytokines were analyzed using a bead-based immunoassay. Statistical analy‑ ses were used to compare histone H3.1 levels between groups and evaluate correlations with clinical parameters and cytokines. Histone H3.1 levels were significantly higher in patients with AIS (271.05 ± 33.40 ng/mL) versus controls (95.33 ± 12.86 ng/mL, p < 0.001). Multivariable logistic regression identified H3.1 as an independent risk factor for AIS (p = 0.006), with an area under the curve of 0.907. Significant correlations were found between H3.1, interleukin-6 (0.290, p = 0.013) and vascular cell adhesion molecule 1 (0.297, p = 0.011). In conclusion, the NETs H3.1 ELISA test is a reliable new diagnostic option that supports the diagnosis of AIS.

Although the proportion of edentulous patients is declining, the aging population has resulted in an increase in their absolute numbers. Conventional complete dentures can partially restore oral function but have significant limitations such as low retention and relatively poor masticatory ability. Therefore, implant overdentures have been proposed as an alternative, offering enhanced functionality, higher patient satisfaction, and cost-effectiveness compared to fixed implants. In this case, a 74-year-old female patient presented with complaints about her existing implant overdenture, fabricated in 2010, which frequently dislodged and was aesthetically unpleasing. Clinical examination revealed worn attachments and artificial teeth, as well as insufficient upper lip support. It was decided to remake the implant overdentures utilizing the existing implants. During the fabrication, the patient continued to use her previous denture. After evaluating the occlusal relationships, facial form, and vertical dimension, the new overdentures were fabricated. The newly created implant overdentures showed satisfactory aesthetic and functional results, and the patient was satisfied.

Although the proportion of edentulous patients is declining, the aging population has resulted in an increase in their absolute numbers. Conventional complete dentures can partially restore oral function but have significant limitations such as low retention and relatively poor masticatory ability. Therefore, implant overdentures have been proposed as an alternative, offering enhanced functionality, higher patient satisfaction, and cost-effectiveness compared to fixed implants. In this case, a 74-year-old female patient presented with complaints about her existing implant overdenture, fabricated in 2010, which frequently dislodged and was aesthetically unpleasing. Clinical examination revealed worn attachments and artificial teeth, as well as insufficient upper lip support. It was decided to remake the implant overdentures utilizing the existing implants. During the fabrication, the patient continued to use her previous denture. After evaluating the occlusal relationships, facial form, and vertical dimension, the new overdentures were fabricated. The newly created implant overdentures showed satisfactory aesthetic and functional results, and the patient was satisfied.

In the 2023 series, we summarized the major clinical research advances in gynecologic oncology based on communications at the conference of Asian Society of Gynecologic Oncology Review Course. The review consisted of 1) Endometrial cancer: immune checkpoint inhibitor, antibody drug conjugates (ADCs), selective inhibitor of nuclear export, CDK4/6 inhibitors WEE1 inhibitor, poly (ADP-ribose) polymerase (PARP) inhibitors. 2) Cervical cancer: surgery in low-risk early-stage cervical cancer, therapy for locally advanced stage and advanced, metastatic, or recurrent setting; and 3) Ovarian cancer: immunotherapy, triplet therapies using immune checkpoint inhibitors along with antiangiogenic agents and PARP inhibitors, and ADCs. In 2023, the field of endometrial cancer treatment witnessed a landmark year, marked by several practice-changing outcomes with immune checkpoint inhibitors and the reliable efficacy of PARP inhibitors and ADCs.

The diagnosis of acute ischemic stroke (AIS) can be challenging when neuroimaging findings are normal or equivo‑ cal. Neutrophil extracellular traps (NETs), particularly histone H3.1, have potential as biomarkers for AIS. This study evaluated NETs, specifically histone H3.1, as diagnostic biomarkers for AIS. This prospective study included 89 patients with AIS and 20 healthy controls. Plasma histone H3.1 levels were measured using the Nu.Q® H3.1 enzyme-linked immunosorbent assay (ELISA). Seven cytokines were analyzed using a bead-based immunoassay. Statistical analy‑ ses were used to compare histone H3.1 levels between groups and evaluate correlations with clinical parameters and cytokines. Histone H3.1 levels were significantly higher in patients with AIS (271.05 ± 33.40 ng/mL) versus controls (95.33 ± 12.86 ng/mL, p < 0.001). Multivariable logistic regression identified H3.1 as an independent risk factor for AIS (p = 0.006), with an area under the curve of 0.907. Significant correlations were found between H3.1, interleukin-6 (0.290, p = 0.013) and vascular cell adhesion molecule 1 (0.297, p = 0.011). In conclusion, the NETs H3.1 ELISA test is a reliable new diagnostic option that supports the diagnosis of AIS.

In the 2023 series, we summarized the major clinical research advances in gynecologic oncology based on communications at the conference of Asian Society of Gynecologic Oncology Review Course. The review consisted of 1) Endometrial cancer: immune checkpoint inhibitor, antibody drug conjugates (ADCs), selective inhibitor of nuclear export, CDK4/6 inhibitors WEE1 inhibitor, poly (ADP-ribose) polymerase (PARP) inhibitors. 2) Cervical cancer: surgery in low-risk early-stage cervical cancer, therapy for locally advanced stage and advanced, metastatic, or recurrent setting; and 3) Ovarian cancer: immunotherapy, triplet therapies using immune checkpoint inhibitors along with antiangiogenic agents and PARP inhibitors, and ADCs. In 2023, the field of endometrial cancer treatment witnessed a landmark year, marked by several practice-changing outcomes with immune checkpoint inhibitors and the reliable efficacy of PARP inhibitors and ADCs.

Although the proportion of edentulous patients is declining, the aging population has resulted in an increase in their absolute numbers. Conventional complete dentures can partially restore oral function but have significant limitations such as low retention and relatively poor masticatory ability. Therefore, implant overdentures have been proposed as an alternative, offering enhanced functionality, higher patient satisfaction, and cost-effectiveness compared to fixed implants. In this case, a 74-year-old female patient presented with complaints about her existing implant overdenture, fabricated in 2010, which frequently dislodged and was aesthetically unpleasing. Clinical examination revealed worn attachments and artificial teeth, as well as insufficient upper lip support. It was decided to remake the implant overdentures utilizing the existing implants. During the fabrication, the patient continued to use her previous denture. After evaluating the occlusal relationships, facial form, and vertical dimension, the new overdentures were fabricated. The newly created implant overdentures showed satisfactory aesthetic and functional results, and the patient was satisfied.

The diagnosis of acute ischemic stroke (AIS) can be challenging when neuroimaging findings are normal or equivo‑ cal. Neutrophil extracellular traps (NETs), particularly histone H3.1, have potential as biomarkers for AIS. This study evaluated NETs, specifically histone H3.1, as diagnostic biomarkers for AIS. This prospective study included 89 patients with AIS and 20 healthy controls. Plasma histone H3.1 levels were measured using the Nu.Q® H3.1 enzyme-linked immunosorbent assay (ELISA). Seven cytokines were analyzed using a bead-based immunoassay. Statistical analy‑ ses were used to compare histone H3.1 levels between groups and evaluate correlations with clinical parameters and cytokines. Histone H3.1 levels were significantly higher in patients with AIS (271.05 ± 33.40 ng/mL) versus controls (95.33 ± 12.86 ng/mL, p < 0.001). Multivariable logistic regression identified H3.1 as an independent risk factor for AIS (p = 0.006), with an area under the curve of 0.907. Significant correlations were found between H3.1, interleukin-6 (0.290, p = 0.013) and vascular cell adhesion molecule 1 (0.297, p = 0.011). In conclusion, the NETs H3.1 ELISA test is a reliable new diagnostic option that supports the diagnosis of AIS.